Simon Krols

PhD Thesis

Breaking bad : development of Aurora kinase A degraders for the treatment of neuroblastoma

Simon Krols (UGent)

(2025)

Journal Article
A1
open access

Second-generation AURKA-targeting PROTACs : structural optimization toward in vivo degradation in neuroblastoma

Simon Krols (UGent) , Muhammad Rishfi (UGent) , Fien Martens (UGent) , Anouk Van Hauwermeiren (UGent) , Ellen Sanders (UGent) , Pieter-Jan De Sutter (UGent) , An Vermeulen (UGent) , Kaat De Wever (UGent) , Sarah-Lee Bekaert (UGent) , M. Emmy M. Dolman, et al.

(2025) JOURNAL OF MEDICINAL CHEMISTRY. 68(22). p.23962-23976

Add to list

Journal Article
A1
open access

Dual N6/C7-substituted 7-deazapurine and tricyclic ribonucleosides with affinity for G protein-coupled receptors

Simon Krols (UGent) , Federica Matteucci, Kristof Van Hecke (UGent) , Guy Caljon, Kenneth A. Jacobson and Serge Van Calenbergh (UGent)

(2023) ACS MEDICINAL CHEMISTRY LETTERS. 15(1). p.81-86

Add to list

Journal Article
A1
open access

Targeted AURKA degradation : towards new therapeutic agents for neuroblastoma

Muhammad Rishfi (UGent) , Simon Krols (UGent) , Fien Martens (UGent) , Sarah-Lee Bekaert (UGent) , Ellen Sanders (UGent) , Aline Eggermont (UGent) , Fanny De Vloed (UGent) , Joshua Robert Goulding (UGent) , Martijn Risseeuw (UGent) , Jan Molenaar, et al.

(2023) EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. 247.

Add to list

Journal Article
A1
open access

Efficient divergent synthesis of new immunostimulant 4″-modified α-galactosylceramide analogues

Jonas Janssens, Tine Decruy (UGent) , Koen Venken (UGent) , Toshiyuki Seki, Simon Krols (UGent) , Johan Van der Eycken (UGent) , Moriya Tsuji, Dirk Elewaut (UGent) and Serge Van Calenbergh (UGent)

(2017) ACS MEDICINAL CHEMISTRY LETTERS. 8(6). p.642-647

Academic Bibliography

Simon Krols

Breaking bad : development of Aurora kinase A degraders for the treatment of neuroblastoma

Second-generation AURKA-targeting PROTACs : structural optimization toward in vivo degradation in neuroblastoma

Dual N6/C7-substituted 7-deazapurine and tricyclic ribonucleosides with affinity for G protein-coupled receptors

Targeted AURKA degradation : towards new therapeutic agents for neuroblastoma

Efficient divergent synthesis of new immunostimulant 4″-modified α-galactosylceramide analogues

Contents

Support

Contact